Interleukin Genetics Inc. Reports Fourth Quarter And Year-End 2014 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2014.
“2014 was an important transition year that positions Interleukin for growth in 2015 and beyond,” said Dr. Kenneth S. Kornman, DDS, PhD, Chief Executive Officer of Interleukin. “Accomplishments during the year included the publication of further supportive scientific data for PerioPredict® and our cardiovascular disease test, the initial market test for PerioPredict®, and the completion of a $10 million financing that provides the support needed to expand our commercialization efforts for PerioPredict® and other testing services.
Help employers find you! Check out all the jobs and post your resume.
“2014 was an important transition year that positions Interleukin for growth in 2015 and beyond,” said Dr. Kenneth S. Kornman, DDS, PhD, Chief Executive Officer of Interleukin. “Accomplishments during the year included the publication of further supportive scientific data for PerioPredict® and our cardiovascular disease test, the initial market test for PerioPredict®, and the completion of a $10 million financing that provides the support needed to expand our commercialization efforts for PerioPredict® and other testing services.
Help employers find you! Check out all the jobs and post your resume.